Enquire

Enrich your medicines pipeline

The research partner that creates innovative solutions, builds dynamic relationships and enriches your medicines pipeline across a range of human diseases

Our Services

Offerings

Research Phases

Therapeutic Areas

Target Classes

Approaches

Case Studies

MAP4K4: Kinase inhibitors for cardioprotection following heart attacks

Domainex designed novel, potent, highly selective, small-molecule inhibitors of MAP4K4, with potential cardioprotective drug properties. View more

Tankyrase: Inhibitors for the treatment of solid tumours

Domainex employed its LeadBuilder virtual screening technology to identify tankyrase inhibitors from which pre-clinical development candidates emerged. View more

Der p 1: Protease Inhibitors for the treatment of asthma

Domainex collaborated with St George’s University London & the University of Manchester on a programme of drug discovery which led to the successfully nomination of a candidate drug. View more

TBK1/IKKε: Kinase inhibitors for the treatment of interferonopathies

Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule orally bioavailable inhibitor of TBK1/IKKε View more

FLIPP-FADD: PPI inhibitors for the treatment of solid tumours

Domainex and Queen's University Belfast have discovered the world’s first inhibitors of FLIP-FADD and produced viable leads for drug candidate selection View more

Ras: PPI inhibitors for the treatment of cancer

Domainex used its extensive experience of fragment- & structure-based drug design to develop a lead molecule with strong binding to RAS, an oncology target. View more

G9a: Lysine Methyltransferase Inhibitors for the Treatment of Cancer

Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a, which have potential to be developed as treatments for a range of solid tumours. View more

G9a: A fragment-based drug design (FBDD) programme to identify lysine methyltransferase inhibitors for the treatment of cancer

Domainex identified several highly efficient fragment hits and after one round of elaboration a 10-fold increase in affinity was achieved. View more

News

How do you plan, implement and adapt your growth strategy?

Tom Mander Introduces Domainex's Medicines Research Centre

Meet the Domainex team: Sam Braidley

Events

Jun 11 OBN Awards

Jun 17 BioForward

Jun 21 BioTrinity 2021

Tweets

Tweets by Domainex_UK

Start your next project with Domainex

Contact one of our experts today